CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
nadololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00670267
NCT00670267Phase 2Completed
CompareCT.gov

An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma

Invion, Inc.·interventional·Posted May 1, 2008·Updated May 11, 2016

In Brief

A Phase 2 clinical trial evaluating nadolol for Asthma. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsUniversity of Houston, Sandler Program for Asthma Research, Baylor College of Medicine

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 1, 2008
Enrollment StartJan 1, 2007
Primary CompletionMay 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.2 years ago

Interventions

nadololdrug

Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.